INTRODUCTION
Metrifonate (O,O-dimethyl-(1-hydroxy-2,2,2-trichloroethyl)-phosphonate) was introduced as a drug for the treatment of schistosomiasis during the 1960s. It has been used extensively in developing countries around the world, and, although it is no longer the first-line medication for this helminthic infection, it remains a World Health Organization approved drug. When used as an antihelminthic, metrifonate is given as a three-dose course of 7. 5 to 15 mg/kg at intervals of 2-4 weeks (a daily dose 8 to 15 times higher than that used for AD).
Based on the results of a comparative pharmacological study with physostigmine, the first cholinesterase inhibitor to be clinically tested in AD, metrifonate was shown to possess a number of pharmacological properties that suggest it is suitable for the treatment of AD (20) . By virtue of its in vitro and in vivo characteristics, metrifonate may be a drug of choice for the cholinergic approach to treating patients with AD (7) . In 1990, the results of the first clinical trial of metrifonate demonstrated the potential for its clinical efficacy in the treatment of cognitive deficits (4) .
Metrifonate is unique as a cholinesterase inhibitor in that it is a prodrug that is non-enzymatically transformed into its active metabolite 2,2-dimethyl dichlorovinyl phosphate (DDVP) (36) (Fig. 1) . The clinical effect of metrifonate is mediated exclusively via the formation of DDVP (25) . Very low concentrations of DDVP steadily released from metrifonate lead to levels that are sufficient to inhibit cholinesterases in vivo. By comparison, if DDVP was to be administered alone, high doses would be required because of its very short plasma elimination half-life (8) . Thus, metrifonate can be viewed as a drug delivery system or reservoir that provides steady, titrated administration of DDVP. The controlled release of DDVP in the brain and slow inhibition kinetics of DDVP for cholinesterase may contribute to the low acute cholinergic toxicity of metrifonate. Alzheimer's disease patients receiving metrifonate generally develop only short-lived and mild cholinergic toxicity (8) . Metrifonate has now undergone phase II and phase III trials, and a New Drug Application (NDA) was submitted to the United States Food and Drug Administration (FDA). Previous reviews have addressed aspects of its pharmacology and acute tolerability in early clinical trials (11, 12, 46) .
CHEMISTRY
Metrifonate is an organic phosphorus compound, which was synthesized by Lorenz and colleagues (31) in 1955 as a condensation product of chloral and dimethyl hydrogen phosphite. Metrifonate is a white or pale yellow crystalline hygroscopic substance, and it is soluble in water (1:7), alcohols, and hydrocarbons. Metrifonate is unstable in alkaline solution.
PHARMACODYNAMIC PROPERTIES

In vitro Studies
Metrifonate by itself does not significantly inhibit cholinesterases. Rather, the inhibitory activity of metrifonate on cholinesterase is mediated by its degradation product DDVP (25) . DDVP inhibits the enzyme acetylcholinesterase (AChE) in a biphasic manner. It first interacts with AChE as a competitive inhibitor, and then, once bound, inhibits this enzyme noncompetitively. The latter inhibition correlates with the progressive CNS Drug Reviews, Vol. 5 phosphorylation of the AChE esteratic site. As AChE binds to the active site, it forms a stable phosphorylated enzyme complex (25) . Phosphorylating agents such as DDVP react covalently with the enzyme to form an inactive phosphoryl enzyme. DDVP forms a dimethoxyphosphoryl enzyme with the phosphate conjugated to the active center serine 203 (49) . Metrifonate inhibits both AChE and butyrylcholinesterase (BuChE) activities in rodent and human brain cortex (19, 21, 41) . DDVP inhibits AChE and BuChE approximately equally in rat brain (i.e., IC 50 = 0.9 nM) but more potently inhibits AChE in erythrocytes compared to BuChE activity in human plasma (IC 50 = 22.5 nM) (18) . Mammalian brain AChE can be separated into multiple molecular forms. The globular tetrameric G4 form and the monomeric G1 form are predominant in the human brain. G1 is almost exclusively intracellular, whereas G4 is extracellular and almost entirely membrane-bound. Both G1 and G4 forms are important for neuronal function and ACh regulation. The presynaptic G4 form is directly involved in the regulation of ACh transmission. AChE and its membrane-associated G4 form are selectively decreased in AD, whereas BuChE and the G1 form are unchanged or only slightly decreased in the brain of AD patients (39) . In rat brain, administration of metrifonate inhibits both monomeric (G1) and tetrameric (G4) molecular forms of AChE (38) .
The nonselectivity of metrifonate for AChE forms may represent a therapeutic advantage over more selective compounds because, by inhibiting both enzymes forms the drug may act throughout the disease process (39, 40) . Considering the progressive decrease in AChE activity taking place in the brain of AD patients and the unvaried level of BuChE activity, a nonselective AChE inhibitor may offer the advantage of a more prolonged effect compared to a more selective AChE inhibitor. In addition, DDVP inhibits equally both G1 and G4 forms of rat and human brain AChE (38, 39) .
Metrifonate and DDVP do not bind to 61 out of 62 mammalian neurotransmitter receptor subtypes, neuropeptide receptors, or ion channel binding sites investigated (23) . Only a slight interaction of DDVP with the nicotine receptor binding site (35 %) was observed (23) . This finding supports the assumption that the therapeutic effect of metrifonate is mediated primarily through a selective activation of the cholinergic system (32) .
In addition to exerting its pharmacological actions through cholinesterase inhibition, metrifonate also inhibits other serine enzymes (esterases and phosphatases), which makes it an attractive potential candidate to regulate amyloid precursor protein (APP) cleavage and APP release as proposed by Mori et al. (33) . These investigators demonstrated that low concentrations of metrifonate significantly increase the release of APPs (but not APPb) from the rat brain cortex (33) . According to these data, metrifonate inhibits AChE by increasing acetylcholine (ACh) levels, and will stimulate muscarinic receptors (mainly M 1 ) and thereby increase the activity of protein kinase C, an enzyme involved in the regulation of the release of nonamyloidogenic APP fragments (Fig. 2) . This mechanism could explain the stabilizing effect of the drug on cognitive deterioration suggested by long-term clinical studies (18) .
In Vivo Studies (Animal Studies)
Metrifonate, administered through various routes, begins to inhibit cholinesterase activity in various regions of rat brain within minutes (20, 21, 24) . Concomitantly and in relation to this enzymatic inhibition, total levels of brain ACh measured with microdialysis are significantly elevated for up to 6 h after a single dose of metrifonate (20, 21) . Consecutive doses of metrifonate will continue to maintain high ACh levels (32) without interfering with ACh accumulation, release, or synthesis in brain (21) . It can be demonstrated, using transcortical microdialysis (without adding a cholinesterase inhibitor in the probe), that metrifonate increases cortical ACh levels in a dose-dependent manner (32) . This increase lasts for several hours and can be reproduced after consecutive doses of the drug (32) . In addition to ACh, metrifonate also elevates norepinephrine and dopamine (but not serotonin) levels in rat cortex (32) . These neurotransmitters are also decreased in AD (17) .
The effects of metrifonate and DDVP on brain cholinesterase activity have been confirmed after oral administration in both young and old rats. Older animals exhibited 30 to 50% higher levels of inhibition and higher levels of ACh (24, 45) . In the rat, complete recovery of cholinesterase activity in blood and brain is attained 24 h after a single oral dose of 100 mg/kg (24) . In aged animals, as in young rats, metrifonate inhibits cholinesterase activity and elevates ACh measured by microdialysis in the brain (26, 45) . The 15-fold increase in cortical ACh levels, which is maintained after 21 d of daily oral metrifonate treatment with no signs of peripheral toxicity is most interesting. This cholinergic, long-term effect (over 21 d) is not seen following the administration of tacrine, another cholinesterase inhibitor tested clinically in AD, over the same period of time (26) . 
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EFFECTS ON MEMORY, LEARNING, AND BEHAVIOR
Behavioral studies utilized the Morris water maze to test reference and spatial memory, reversal learning, and active-or passive-avoidance foot shock and to examine behavior in normal adult, aged, brain-lesioned, or scopolamine-treated memory-impaired rats.
Oral administration of metrifonate enhanced reference memory and passive-avoidance behavior in older rats but only passive avoidance in very aged rats (>24 m) (10, 27, 44, 51) . In scopolamine-treated rats, metrifonate restored reference memory and reversal learning (27, 44) . In rats with basal forebrain or medial septum lesions, metrifonate improved reference memory and reversal learning and restored passive avoidance behavior (27, 43, 44) . Of particular interest is the simultaneous and related effect of metrifonate on brain ACh levels and object recognition in aged rats (45) .
Other effects of metrifonate include increases in neocortical electroencephalogram arousal (9) and local cerebral glucose utilization, compensating for age-related hypometabolism in rats (3). Metrifonate treatment also enhances acquisition of eye-blink conditioning and improves associative learning and retention in aging rabbits (29, 30) .
Neither metrifonate nor DDVP show analgesic effects or effects on motor coordination; these agents shorten duration of hexobarbital-induced anaesthesia, lower body temperature, and do not show convulsive effects in rodents (23) .
ANIMAL TOXICITY
In the development of any new drug for a new indication, there must be concern for long-term toxicity, especially for a medication that has multiple neurotransmitter effects, such as a cholinesterase inhibitor.
No signs of neurotoxicity were found in chickens, which represents the most sensitive test object for organophosphate neurotoxicity either at single maximum-tolerated doses or chronic doses (addition to the diet for prolonged periods of time up to six months). When metrifonate was tested in chickens using s.c. doses up to 800 mg/kg (53), oral doses up to 100 mg/kg, i.p. doses up to 500 mg/kg, or by feeding high doses for 4-29 w (48), no signs of neurotoxicity, including neuromuscular toxicity, could be demonstrated. In other experiments, neither metrifonate (16) nor DDVP (2, 14) were reported to be neurotoxic to hens.
Rhesus monkeys treated with various doses of metrifonate for a period of 10 years did not show tissue pathology (including liver morphology), tumorigenicity, or specific toxic changes in organ systems including the central nervous system (CNS) and muscle system (45) . An extensive review of the toxicological and pharmacological studies of metrifonate in the treatment of schistosomiasis has been conducted by Holmstedt et al. (26) . The major side effects of metrifonate were similar to the typical cholinergic effects reported for other cholinesterase inhibitors.
Holmstedt et al. emphasize that, in spite of its extensive use in humans, metrifonate has been involved in very few adverse treatment effects in western Europe, the Americas, or Australia, and it has been used with at least as much safety as other anthelmintics. Humans have been known to ingest up to 4.5 g of DDVP in a single dose, after which they exhibited the usual cholinergic symptoms but no polyneuritis (52) . A detailed study on delayed neurotoxicity conducted by Johnson (28) examined whether or not DDVP causes delayed neuropathy in humans or test animals. This study concluded that, to obtain critical levels of neurotoxic esterase inhibition and to cause neuropathy in humans with repeated doses, severely toxic and perhaps lethal doses are required. Therefore, DDVP ingested in large doses is more likely to be lethal than to cause neuropathy. Although these data cannot be generalized to patients with AD, and DDVP is the metabolite of metrifonate, recent clinical findings suggest that metrifonate has low toxicity at clinical doses used for AD (13, 41) .
It is of concern, however, that approximately 20 out of 3000 patients in the metrifonate clinical studies developed "asthenia, myasthenia, and malaise," and "four patients with muscular weakness received respiratory support" (personal communication, Bayer Pharmaceuticals, 1998). "Asthenia" or "myasthenia" are terms used by Bayer Pharmaceuticals to indicate weakness and should not be confused with myasthenia gravis. Currently, metrifonate has been withdrawn from subjects, and the development program has been temporarily halted by Bayer and the FDA in order to investigate this matter further.
HUMAN PHARMACOKINETIC PROFILE
Pharmacokinetic data for metrifonate and DDVP are available for healthy young and elderly subjects and for AD patients. These data reflect single and multiple oral doses and are summarized in Table 1 .
In general, in late middle-aged subjects (mean age 62-64 y), metrifonate is rapidly absorbed with an average time to maximum concentration (t max ) of 20-30 min, a maximum concentration (C max ) of approximately 1.2 mg/L (1.5 mg/kg dose), and an elimination half life (t 1/2 ) of 2 h C max increases linearly with dose. As expected by its metabolism, the t max of DDVP (30-60 min) lags behind that of metrifonate, although it is extremely variable. The maximal DDVP concentration is about 3% to 5% that of metrifonate. The t 1/2 of DDVP is slightly longer than that of metrifonate (2.5 h).
Concomitant administration of metrifonate with food prolongs its t max , reduces its C max , and modestly reduces its availability and cholinesterase inhibition when compared to the fasting state.
Human Pharmacodynamics Studies
Human studies of metrifonate have been ongoing for the past four decades. Studies of metrifonate in AD were undertaken only in the last 12 years. In the early studies of metrifonate in the treatment of AD, weekly dosing regimens were used. These dosing regimens resulted in variable levels of AChE inhibition (approximately 40 to 90%) with some degree of intraindividual variation throughout the 1-w dosing interval. In order to minimize the between-dose variability in cholinesterase inhibition, studies were undertaken using a daily dosing regimen, thus ensuring more stable steady-state level of cholinesterase inhibition.
Following single-dose oral administration of metrifonate in humans, two phases of red blood cell AChE inhibition are observed (22) . First, there is a relatively rapid phase of inhibition which is followed by a second, slower recovery phase of enzyme activity, which L. S. SCHNEIDER AND E. GIACOBINI occurs approximately 8 h after peak inhibition. The second phase relates to new enzyme synthesis (enzyme "reactivation"). Plasma BuChE activity rapidly approaches zero, remains low during the next 8 h, and recovers slowly after the first day. AChE activity in erythrocytes drops to 20 to 40% of basal value and recovers more slowly than plasma BChE activity. As indicated by these times, enzyme inhibition persists after DDVP has been cleared from the blood. Reversal of cholinesterase inhibition is slow and correlates with enzyme resynthesis (31) . Despite a high level of AChE and BuChE inhibition (80 to 90%), cholinergic side effects are mild (complaints of slight dizziness or nausea, usually without vomiting) (22, 35) .
The studies of Nordgren et al. (35) demonstrated that after oral administration of metrifonate (10 mg/kg) in humans, the amount of DDVP found in plasma is about 1% of that of the prodrug and possibly about 3% in older subjects (31) . Similar findings have been reported by Pettigrew et al. (41) . Considering both the slow biotransformation of metrifonate into the active compound, and the possibility that cholinergic side effects are related to the rate of change in enzyme inhibition, the marked peak/trough fluctuations in enzyme inhibition, and a rapid gradual increase of brain ACh (20, 21) , a once-daily dosing regimen for metrifonate seems to be most appropriate for treatment purposes.
In some clinical studies, a loading/maintenance regimen has been used to more rapidly attain steady-state enzyme inhibition (22) . Loading doses administered for 6 d and mainte- nance doses given for 4 weeks to elderly nonAD subjects produced steady-state levels of AChE inhibition of 62 to 72% (low-and high-dose regimens) with very mild side effects (22) . Enzyme recovery half-life was 9 to 11 d for BuChE and 47 to 55 d for AChE. In phase II and phase III trials of metrifonate in patients with AD, the loading-dose period was generally 2 weeks. A subsequent study evaluating the clinical benefits of a loading-dose phase showed that such a dosing regimen offered no clear benefit (41) . Evidence that metrifonate penetrates the CNS includes the close brain ratio of AChE inhibition/ACh levels seen in rats, and the 40% AChE inhibition measured in patients 24 h after a second weekly dose of 5 mg/kg (4, 20, 32) .
THERAPEUTIC TRIALS
As previously mentioned, early metrifonate trials tended to use weekly doses, whereas later trials used once-daily-doses to reduce fluctuation between peak and trough inhibition levels and resulted in a more stable level of AChE inhibition (41) . The earlier randomized clinical trials were dose-ranging studies followed by individualized dosage studies. Both studies used a loading-dose for the first several weeks of treatment. The phase III studies tended to use single individualized dosages or a fixed dose. Selected metrifonate clinical trials are summarized in Table 2 .
Various doses of metrifonate were associated with significant cognitive improvement compared to placebo. Higher doses were consistently more effective than lower doses. In addition, in most trials, there was improvement in the Clinician's Interview-Based Impression of Change (CIBIC) scale or on the Global Clinical Impression (GCI) scale, indicating that not only was there measurable cognitive improvement, but there was also a clinically meaningful improvement that could be observed.
There were generally significant drug-placebo differences in activities of daily living measures, but these differences often depended on sample size and the characteristics of the instruments used. In one trial of particular note (34) , patients who received metrifonate over the course of 6 months were rated as significantly better than placebo on both cognitive and global ratings, and a behavioral rating instrument, the Neuropsychiatric Inventory. Individual behavioral items that may have contributed to this difference included hallucinations, depression, apathy, and motor behavior.
Critical review of the results from the low-dose clinical trial indicates that the magnitude of cognitive improvement associated with metrifonate treatment is comparable to that observed with other cholinesterase inhibitors and reflects the expected deterioration in the placebo group combined with no change or a small cognitive improvement in the metrifonate group. The magnitude of improvement on the CIBIC scale is also similar to that observed in other cholinesterase inhibitor studies; however, higher dose studies are currently being analyzed.
Although it is too early to assess potential predictors of response to metrifonate in view of suggestions that the presence or absence of an apolipoprotein E4 (ApoE4) allele might influence response to tacrine (another cholinesterase inhibitor) (15,47), Becker and colleagues observed that AD patients treated with 2.1 mg/kg metrifonate over the course of 18 months and carrying at least one ApoE4 allele did not respond to metrifonate treatment compared to nonApoE4 carriers (unpublished data).
HUMAN TOLERABILITY AND SAFETY
Metrifonate is generally well-tolerated (Tables 2 and 3 ). The vast majority of metrifonate-treated patients enrolled in phase III studies completed these clinical trials. Significant side effects occurred in no more than 11% of patients receiving higher doses. Most adverse events were cholinergically mediated and are characteristically mild in severity and short lived, lasting only a few days. Patients tend to rapidly become tolerant to the adverse events when they occur. The most commonly reported adverse events included diarrhea, flatulence, leg cramps, and rhinitis (34) .
A modest decrease in heart rate at higher doses of medication (∼5 bpm) is almost certainly due to the vagotonic effects observed with this class of compound. The increased incidence of leg or muscle cramps has also been reported with other cholinesterase inhibitors. The most obvious reason for these side effects is tonic stimulation of myoneural nicotinic receptors.
Cholinesterase inhibitors require caution when used in patients with significant asthma, significant chronic obstructive pulmonary disease, cardiac conduction defects, or clinically significant bradycardia. This caution is potentially important in view of the potential for respiratory impairment causing a halt to the ongoing trials.
The effects of long-acting cholinesterase inhibitors suggest that regional or local anesthesia should be used if surgery is needed (if possible). Physicians should consider that metrifonate might decrease the activity of BuChE. Also, short-acting muscle relaxants that are not metabolized via BuChE may be used and higher doses of muscle relaxants may be required because of increased intrasynaptic ACh.
DOSAGE AND ADMINISTRATION
Most of the development studies used a loading dose for 2 w coupled with an individualized maintenance dose (30-80 mg/d). One clinical trial used a fixed 50-mg/d dosage. As a schistosomiasis treatment, metrifonate is available in tablet form. As an AD treatment, metrifonate will likely be available in 50-, 60-, and 80-mg tablets to be taken once daily.
SUMMARY
As a cholinesterase inhibitor, metrifonate has a number of unique characteristics. Its biphasic and stable binding through phosphorylation of the cholinesterase enzyme causes a long-lasting enzyme inhibition. Relatively high and consistent levels of cholinesterase inhibition can be achieved with once-daily metrifonate and appear to be related to clinical response. The ability to maintain constant levels of cholinesterase inhibition may also be responsible for the high degree of tolerability of metrifonate with respect to cholinergic side effects. Several 6-month studies have shown clear cognitive and clinical efficacy. Phase IV trials will need to be carried out to provide additional information about the Not reported LOCF analysis. Significant drug-placebo difference on behavior as measured by the NPI (3.4 points); agitation and agression, aberrant motor behavior were significant; also significant effect on MMSE and ADLs Study 0115 ("MALT"). Placebo-controlled, parallelgroup, dose ranging (2 ranges and placebo), oral loading doses daily for 2 w followed by maintenance doses for next 26 w Figures are abstracted from references or reports but are approximate because of changing sample size and variabilities in the analyses. Dropouts are for all reasons to avoid bias, not just those attributed to side effects. Adverse events listed are those occurring significantly more often (or sometimes 5% more often) than placebo at the highest metrifonate dose. Outcome-effect sizes are drug-placebo differences and are based on the highest dose used in the trial and on the more conservative (modified) ITT analyses. All effects listed are statistically significant ( p < 0.05). Differences in outcome are not strictly comparable among studies, especially on clinicians "global" ratings, and should be used as a guide only since actual differences depend on statistical model and type of analysis and are not performed consistently from study to study.
overall efficacy of metrifonate and to resolve safety issues. With respect to efficacy, metrifonate compares favorably with other cholinesterase inhibitors.
